透析患者的认知障碍:我们可以预防吗?
Mehmet Kanbay1, Berk Mizrak2, Sidar Copur2
1Department of Medicine, Koc University School of Medicine, Istanbul, Turkey.
Journal of nephrology
|September 21, 2024
概括
认知障碍在慢性病 (CKD) 和透析患者中很常见,影响了超过一半接受替代疗法的患者. 早期查和管理至关重要,因为目前对于这种疾病没有批准的治疗方法.
科学领域:
- 腎臟病學 (nephrology) 是一種醫學專業.
- 神经学 神经学
- 公共卫生 公共卫生
背景情况:
- 慢性病 (CKD) 影响全球10%以上的成年人,对发病率和死亡率作出重大贡献.
- 认知障碍在CKD患者中很普遍,随着疾病的发展阶段而恶化,并影响超过50%的置换疗法患者.
- 缺乏认可治疗的认知障碍在CKD强调需要有效的预防和查策略.
研究的目的:
- 要突出慢性病 (CKD) 患者认知障碍的重大负担.
- 讨论在透析患者中评估认知功能的挑战.
- 强调查的重要性以及对CKD认知障碍的潜在治疗或预防选择.
主要方法:
- 对CKD和透析中认知障碍的现有文献的审查.
- 分析拟议的预防和治疗策略.
- 讨论当前评估实践中的挑战.
主要成果:
- 认知障碍与CKD阶段有很强的相关性,并且在接受置换治疗的患者中非常普遍.
- 各种干预措施,如红色素治疗,运动和透析调整,都显示出不同的疗效.
- 对认知障碍的查对于及时诊断和管理至关重要,尽管对这一群体的验证工具存在局限性.
结论:
- 认知障碍是CKD的主要并发症,需要主动管理.
- 在维持透析患者中,定期查认知障碍对于改善患者护理至关重要.
- 需要进一步开发针对慢性病患者的验证评估工具,以克服当前的实践挑战.
相关概念视频
Dialysis
276
Renal failure occurs when the kidneys lose their ability to filter waste products from the blood effectively. It can be classified into two types: acute renal failure (ARF) and chronic renal failure (CRF).
Acute kidney injury develops suddenly and can be caused by pre-renal causes (e.g., hypovolemia, shock), intrinsic renal causes (e.g., acute tubular necrosis), or post-renal causes (e.g., urinary obstruction). In contrast, chronic renal failure progresses gradually over time and is often...
Acute kidney injury develops suddenly and can be caused by pre-renal causes (e.g., hypovolemia, shock), intrinsic renal causes (e.g., acute tubular necrosis), or post-renal causes (e.g., urinary obstruction). In contrast, chronic renal failure progresses gradually over time and is often...
276
Cognitive Development During Adulthood
66
Cognitive development continues throughout adulthood, undergoing significant shifts across early, middle, and late stages. Individual transition occurs from adolescent idealism to pragmatic and adaptable thinking in early adulthood. During this period, individuals learn to integrate personal beliefs with the recognition that other perspectives are equally valid. Exposure to the complexities of modern society, diverse experiences, and higher education contribute to this adaptive thought process,...
66
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
107
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
107
Factors Affecting Renal Clearance: Renal Impairment
61
Renal dysfunction significantly impairs the renal clearance of drugs, leading to potential complications in drug therapy. Renal failure, which can be caused by various factors, poses a significant challenge in the elimination of drugs from the body.
One condition associated with renal failure is uremia. Uremia is characterized by impaired glomerular filtration and fluid accumulation in the body. This condition hinders the renal clearance of drugs, resulting in drug accumulation and potential...
One condition associated with renal failure is uremia. Uremia is characterized by impaired glomerular filtration and fluid accumulation in the body. This condition hinders the renal clearance of drugs, resulting in drug accumulation and potential...
61
Dementia
102
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
102
Alzheimer's Disease: Treatment
170
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
170


